Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crizotinib in Patients With MET-Amplified NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2021

Camidge D Ross, Otterson Gregory A, Clark Jeffrey W, Ignatius Ou Sai-Hong, Weiss Jared, Ades Steven, Shapiro Geoffrey I, Socinski Mark A, Murphy Danielle A, Conte Umberto, Tang Yiyun, Wang Sherry C, Wilner Keith D, Villaruz Liza C

Abstract excerpt

INTRODUCTION: MET amplification is a rare, potentially actionable, primary oncogenic driver in patients with NSCLC. METHODS: The influence of MET amplification on the clinical activity of the ALK, ROS1, and MET inhibitor, crizotinib (250 mg twice daily), was examined in patients with NSCLC (NCT00585195) who were enrolled into high (≥4 MET-to-CEP7 ratio), medium (>2.2 to <4 MET-to-CEP7 ratio), or low (≥1.8 to ≤2.2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to In Situ Hybridization, Fluorescence

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Identifiers

PMID: 33676017
DOI: 10.1016/j.jtho.2021.02.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crizotinib in Patients With MET-Amplified NSCLC.PMID 33676017Read ↗

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsSemantic proximity Read ↗

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.Semantic proximity Read ↗

Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.Semantic proximity Read ↗

Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.Semantic proximity Read ↗

Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy.Semantic proximity Read ↗

Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer.Semantic proximity Read ↗

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.Semantic proximity Read ↗

Targeting MET Dysregulation in CancerSemantic proximity Read ↗

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

MET-dependent solid tumours - molecular diagnosis and targeted therapy.Semantic proximity Read ↗

Targeting MET in EGFR-Mutated NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.